SCROLL DOWN
Innovation
Longevity Products
Access & Equity
Research & Funding
Drug Development
Policy
In 2024, women’s health experienced a turning point that many called “the year of reckoning.” Research funding for female-specific conditions surged to record levels, with major breakthroughs in understanding conditions like endometriosis and menopause-related symptoms. Artificial intelligence emerged as a transformative tool, enabling faster, more accurate diagnoses for conditions like breast cancer and osteoporosis, while personalized medicine made significant strides, tailoring treatments to the unique hormonal and genetic profiles of women. On the policy front, the push for paid family leave gained critical traction in several states, and federal legislation targeted systemic healthcare inequities, particularly for women of color and those in rural areas. Meanwhile, innovation flourished, with the launch of menopause-focused medications that finally addressed both symptoms and long-term health risks. These advancements not only raised the standard of care but set the stage for 2025—a year projected to bring even more seismic changes. From the rise of AI-powered fertility tools to historic investments in longevity science, 2025 is shaping up to be a year where women’s health will leap from progress to transformation. What better way to welcome the new year than by exploring the groundbreaking trends, innovations and policies poised to redefine women’s health and well-being in the year ahead?
In 2025, innovation will be the driving force transforming women’s health from reactive care to a proactive, personalized experience. From groundbreaking diagnostic tools to wearable devices that offer real-time insights, the future is leaning into artificial intelligence (AI) with women’s unique biological needs in mind.
This year, longevity products will take center stage in women’s health, shifting the focus from simply living longer to living better. These breakthroughs aim to tackle the challenges of aging by addressing the unique health concerns women face, from cognitive decline to hormonal changes.
In 2025, healthcare access and equity will remain key issues, but innovative solutions are emerging to break down barriers, particularly for women. Digital health platforms, telemedicine and AI tools are expanding access, allowing women—especially those in underserved areas—to connect with vital healthcare resources.
According to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM), only 8% of NIH research funding is allocated to women’s health—down from 11% in 2019. As we look ahead to 2025, the landscape of women’s health is poised for a transformative shift, largely fueled by groundbreaking research and targeted funding initiatives.
The landscape of women’s health medications is set to undergo a major transformation in 2025, driven by new discoveries and an increased focus on gender-specific needs.
In recent years, the intersection of policy and women’s health has been marked by both progress and challenges. As 2025 approaches, the role of legislation in shaping the future of women’s healthcare has never been more critical.
Read More
HOME
In 2025, innovation will be the driving force transforming women’s health from reactive care to a proactive, personalized experience. From groundbreaking diagnostic tools to wearable devices that offer real-time insights, the future is leaning into artificial intelligence (AI) with women’s unique biological needs in mind. Innovations in femtech, biotech and digital health are not just addressing overlooked areas of care but also making solutions more accessible and actionable. These advancements promise to close gaps in understanding conditions like menopause, menstrual health and brain health, while providing tools that empower women to take control of their well-being. As we look ahead, the fusion of cutting-edge technology and a more inclusive approach to healthcare is set to redefine what’s possible in women’s health.
AI is helping detect conditions like breast cancer and lupus more quickly and accurately by analyzing data in ways that were never possible before. For example, by reviewing imaging scans or hormonal pattern analysis, we can identify subtle changes that are often missed by traditional methods.
Innovation will take center stage in women’s health in 2025, as groundbreaking technologies move from concept to mainstream care. One area experts believe will spearhead this move is artificial intelligence (AI). Once confined to research labs, AI is now shaping everyday healthcare experiences, with AI-powered tools offering faster, more accurate diagnostics and personalized treatment plans. “AI is transforming early detection by analyzing medical images like mammograms and ultrasounds with a level of accuracy and speed that outperforms traditional methods,” explained Sheena Franklin, founder and CEO of K’ept Health, a women’s health informatics company committed to redefining healthcare for women through advanced data-driven insight. Beyond imaging, Franklin says AI-powered tools can be applied to shifting through large data sets of patient history and genetic data to identify women at higher risk for particular diseases to improve preventative care and early intervention activities. She explains that advancements in technology are making it easier for patients and their physicians to catch issues early, receive personalized care and access doctors whether you live in large urban areas or rural/coastal areas—and across socioeconomic status. “AI is helping detect conditions like breast cancer and lupus more quickly and accurately by analyzing data in ways that were never possible before. For example, by reviewing imaging scans or hormonal pattern analysis, we can identify subtle changes that are often missed by traditional methods,” Franklin says. In November, the U.S. National Science Foundation (NSF) hosted a landmark workshop, "Using AI to Better Understand Menopause," which brought together experts from the biomedical and computing fields. The discussion explored how AI can analyze data to reveal patterns that traditional research methods may miss. Panelists also acknowledged challenges that need to be addressed, including the lack of relevant health data. “Menopause and perimenopause are so widely experienced, yet so rarely discussed, and too rarely researched,” Karen Marrongelle, NSF chief science officer, said during the panel. “In bringing leading experts in women’s health together with experts in AI, and designing new programs informed by their insights, NSF is elevating and expanding necessary conversations about the challenges of menopause while accelerating research to find solutions.” AI is also poised to transform education in women’s health. Cristina Manole, founder and chief visionary officer of FemTech Sphere—a platform that supports women’s health startups by connecting them with industry experts and investors—sees tremendous potential for AI-driven tools to enhance learning and collaboration across the sector. “I think the possibilities are infinite when using AI. It could help clean the muddy data that we have collected in healthcare and really focus on what is actually relevant and continue that research,” Manole says. "Data is knowledge, and knowledge is power. Once we gather more data, we can build on existing information from companies that have already created solutions.” Researchers at the University of Edinburgh are at the forefront of integrating AI into healthcare with the development of a groundbreaking screening method for breast cancer. In December, the team unveiled a pioneering approach that combines laser analysis with AI technology, marking a first-of-its-kind advancement in detecting patients at the earliest stage of the disease. This innovative, fast and non-invasive technique identifies subtle changes in the bloodstream that occur during stage 1a breast cancer—an early phase that current tests cannot detect, according to the researchers. "Most deaths from cancer occur following a late-stage diagnosis after symptoms become apparent, so a future screening test for multiple cancer types could find these at a stage where they can be far more easily treated,” Dr. Andy Downes, a leading researcher from the University of Edinburgh's School of Engineering, who spearheaded the study, said in a press release. “Early diagnosis is key to long-term survival, and we finally have the technology required.” By refining and updating this data, comparing it with new research and identifying what’s most relevant, Manole says researchers can create solutions that truly address women’s needs. AI plays a vital role in this process—not only in analyzing and refining data but also in informing and empowering women. “That’s so important because I feel strongly that it’s an injustice for women not to have access to the knowledge they need about their own health,” Manole says.
The Forecast Ahead
This year, longevity products will take center stage in women’s health, shifting the focus from simply living longer to living better.
In 2025, healthcare access and equity will remain key issues, but innovative solutions are emerging to break down barriers, particularly for women.
Intro
Precision Medicine Expansion
Digital Health Ecosystems
Self-testing for Cancer
Artificial Intelligence Integration
For the longest time, health conditions that target women were overlooked thanks in large part to women being underrepresented in medical research. In 1977, the FDA recommended excluding women of childbearing age from drug trials due to concerns about how menstrual cycles, hormonal fluctuations and contraception might skew results. While the NIH introduced a policy for including women in clinical research between 1989 and 1993, it wasn’t until the NIH Revitalization Act of 1993 that Congress mandated their inclusion by law under the “Women and Minorities as Subjects in Clinical Research” provision. Since then, we’ve made significant progress, and in 2025, experts predict that precision medicine will transform women’s healthcare. By leveraging genetic, hormonal and microbiome data, this approach will enable highly personalized therapies tailored to each individual’s unique needs, significantly impacting conditions like polycystic ovary syndrome (PCOS), menopause and postpartum depression, which often have complex, varied presentations and responses to treatment. “Women-led startups and organizations with targeted patient advocacy strategies drive innovation by centering care around women’s unique needs,” Franklin founder says. “Advocacy efforts that focus on prioritizing patient education, fostering open communication with providers, and tools to help women advocate for themselves will reshape how care is delivered.”
Imagine a platform where a woman can schedule a virtual appointment with a gynecologist, access a therapist specializing in postpartum mental health, and receive tailored fertility advice—all within the same app. In 2025, startups will continue to reshape the landscape of womens healthcare by developing comprehensive digital health platforms. These ecosystems will seamlessly integrate telehealth for virtual consultations, mental health support tailored to women’s unique needs—including menopause care—and fertility services ranging from ovulation tracking to IVF monitoring. Companies like Tia, Midi Health and Alloy have already pioneered these all-in-one platforms, with many more expected to follow suit, expanding access to personalized and comprehensive women’s health solutions. “We have seen a broadening of the definition of women’s care beyond fertility—this includes the lived experience and health challenges of women in menopause,” Dr. Kathleen Jordan, chief medical officer at Midi Health, the nation’s largest menopause care platform, says. “We’ve seen exponential growth of companies like Midi Health, alongside a surge in Menopause Society memberships and a rapidly expanding list of certified providers.” By combining these services into a single, user-friendly platform, Jordan believes these innovations aim to provide women with seamless, one-stop solutions for managing their health. Many of these ecosystems will also incorporate AI-driven insights, empowering users with personalized recommendations based on their health history, hormonal data or lifestyle factors. PatientsLikeMe—the world’s largest personalized health network connecting patients and helping them discover new treatments—recently unveiled Ella, an AI-powered health assistant developed in collaboration with Ema. Designed to support women’s health and wellness across all life stages, Ella delivers personalized, evidence-based guidance tailored to each user’s unique needs. “What makes this project particularly impactful for underserved populations is its focus on delivering tailored support,” Dr. Kate Burke, senior medical advisor at PatientsLikeMe, says. “By combining expert medical knowledge with real world patient experiences, Ella offers accessible, understandable health information to patients who might otherwise struggle to access medical advice.” Burke emphasizes that collaboration among women-led companies, patients and healthcare providers is key to ensuring the real-world effectiveness of new innovations. This collaborative ecosystem drives the development and scaling of impactful solutions, ultimately shaping the broader healthcare landscape.
Self-Testing for Cancer
Another area of innovation that experts predict will grow in 2025 is self-testing kits for cervical cancer, which we already began to see in 2024. Companies like Roche and Becton, Dickinson and Company (BD) are transforming HPV detection by eliminating the need for a traditional pelvic exam performed by a doctor. Instead of the conventional method, which involves scheduling a doctor’s appointment and having a sample collected from the cervix, women can now opt for a self-collection process conveniently done at the doctor’s office. Researchers from Sweden's Karolinska Institutet and Queen Mary University of London have confirmed that self-testing could significantly enhance cervical screening efforts. Their recent study analyzed 855 women who tested positive for HPV through a self-test and later had a clinician-collected sample. Researchers found that 71 women had severe cervical changes that could lead to cancer and examined two factors to assess their risk: the type of HPV and the viral load, measured by the cycle threshold (Ct) value. A low Ct value (below 30) indicates a high viral load, increasing the risk of severe cervical changes. This method allowed for immediate risk categorization after an HPV self-test, without the need for further lab analysis. "Self-testing for HPV has become an important component in cervical screening. It reaches women who would not otherwise participate," Jiayao Lei, assistant professor at the Department of Medical Epidemiology and Biostatistics and the Department of Clinical Science, Intervention and Technology, said in a press release. The Centers for Disease Control and Prevention (CDC) states that HPV causes 90% of cervical cancer cases, yet one in four women in the U.S. are not current with their screenings. However, with the increasing availability of self-tests and ongoing research, such as studies from Sweden's Karolinska Institutet, the future of cervical cancer screenings may be transforming.
Sheena Franklin
CEO of K'ept Health
founder and chief visionary officer of Femtech Sphere
Cristina Manole
I feel strongly that it’s an injustice for women not to have access to the knowledge they need about their own health.
This year, longevity products will take center stage in women’s health, shifting the focus from simply living longer to living better. These breakthroughs aim to tackle the challenges of aging by addressing the unique health concerns women face, from cognitive decline to hormonal changes. Cutting-edge advancements, including brain health monitoring devices, menopause-specific therapeutics and tools leveraging biomarkers from menstrual blood, are poised to enhance early detection, prevention and personalized care. As innovation meets longevity science, these products are not only extending healthspan but also empowering women to thrive through every stage of life.
In addition to AI, a growing number of companies are developing wearables that track everything from sleep patterns to menstrual cycles, providing women with real-time insights into their health. While you're likely familiar with devices like the Apple Watch or Oura Ring, emerging technologies are taking it a step further, offering women unparalleled access to personalized health insights and feedback. According to Dr. Kathleen Jordan, chief medical officer at Midi Health, 2025 will see a significant rise in home diagnostics and wearable health monitors, offering more convenience and control over women's health than ever before. “Women are now taking charge of their health by monitoring their own blood pressure with wearables, tracking glucose levels and testing hormone levels through at-home collection tests,” Jordan says. “This shift has the potential to increase access to care, making it possible to receive support from virtually anywhere—as long as there’s phone or internet access.” Meanwhile, advancements in menstrual pain management have also emerged. The UK brand Myoovi introduced a wearable device using transcutaneous electrical nerve stimulation (TENS) technology to provide a drug-free, FDA-approved alternative for relieving menstrual cramps. TENS works by emitting electrical signals that disrupt pain signals traveling to the brain, effectively reducing the perception of pain.
According to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM), only 8% of NIH research funding is allocated to women’s health—down from 11% in 2019.
Advanced Brain Monitoring
Menstrual Blood Diagnostics
Modifying IUD Insertion
Wearables
In 2025, advanced brain monitoring products will play a key role in transforming how we understand and manage cognitive health, particularly for women. Wearable devices with cutting-edge neurotechnology, such as EEG sensors and brainwave analysis, will allow for real-time tracking of brain activity, enabling early detection of cognitive decline, stress and mental health conditions like depression and anxiety—issues that disproportionately affect women, especially during menopause and later in life. These innovations will help women track their brain health over time, catching subtle changes that might otherwise go unnoticed until they become more significant. One company leading the way is Advanced Brain Monitoring, which has developed products like the BEAM™ and Sleep Profiler™. The BEAM™ combines EEG (which measures brain electrical activity) with automated cognitive tests to analyze brain function. By comparing results to a large database, it can detect early signs of cognitive decline, identify types of dementia, track disease progression and evaluate treatment effectiveness—allowing for more personalized care for patients with neurological conditions. The Sleep Profiler™ EEG Sleep Monitor is a wireless, at-home device that tracks sleep by measuring brain waves (EEG), eye movements (EOG) and muscle activity (EMG). It provides valuable insights into sleep quality and brain health by monitoring different sleep stages. These devices empower women with personalized insights, enabling early detection and better management of brain health. “We want doctors to think about brain health in the same way they consider mammograms and colonoscopies,” says Chris Berka, CEO and co-founder of Advanced Brain Monitoring. “Preventative care is crucial, especially for brain health. Our devices are designed to help clinicians identify specific subsets of dementia, like Alzheimer’s disease and Lewy Body disease, and get patients on the right care plans.” Women are disproportionately affected by Alzheimer’s, with nearly two-thirds of those diagnosed being female. This is partly due to women’s longer life expectancy. On average, women live 4.2 years with mild cognitive impairment and 3.2 years with dementia, compared to men who experience 3.5 years with mild cognitive impairment and 1.8 years with dementia. “At Advanced Brain Monitoring, we want to help clinicians properly identify the subset of dementia and ensure treatment is offered as soon as possible,” Berka says. “The biggest challenge for us right now is reimbursement.” Given the tight margins hospitals face, Berka believes portable, affordable devices are a smart cost-effective solution. They complement the more expensive machines already in use at hospital systems, while also making brain health more accessible to a wider range of patients.
Another game-changing product with the potential to transform women’s healthcare is the innovative use of menstrual blood. One company already implementing this is Qvin with their Q-Pad, which is the first and only FDA-approved menstrual pad, scientifically proven to collect blood for diagnostics. “I think menstruation is truly having a moment,” Sara Naseri, co-founder and CEO of Qvin, says. “It is a big moment for women's health to say, ‘look, this thing that is so natural and happens to every woman is not a waste product. It's not a stigma, it's not a taboo. It's actually an incredible opportunity for women to get insights about what's going on in their bodies.’” Because menstrual blood contains a variety of substances—endometrial tissue, proteins, hormones, metabolites and even microorganisms—Naseri explains it can offer valuable insights into a woman's health. The blood itself contains red and white blood cells, which can indicate underlying conditions like anemia or inflammation. The presence of endometrial tissue and mucus can reveal issues related to the reproductive system, such as endometriosis or polyps. Hormones like estrogen and progesterone fluctuate throughout the menstrual cycle, so analyzing their levels in menstrual blood can provide clues about hormonal imbalances, fertility issues and conditions like polycystic ovary syndrome (PCOS) or menopause. “There's a lot that we need to continue to understand to be able to have the impact I think menstrual blood can have in the clinic. Not just in the U.S., but even when you think about abroad,” Naseri says. “A lot of women don't have access to an OB-GYN, and this could be a very powerful way to actually give them care.” The Q-Pad A1c Test, one of the Q-Pad’s key features, uses menstrual blood to measure average blood sugar levels through the A1c biomarker, providing valuable insights into a woman's metabolic health without the need for a traditional blood draw. The Q-Pad is a menstrual pad designed with specialized technology to collect blood in a way that preserves its integrity for testing. This needle-free method allows women to easily collect menstrual blood at home and send it to a lab for analysis, making it easier to monitor reproductive health, hormone levels and even track chronic conditions like diabetes. By offering a simple, comfortable alternative to traditional blood tests, the Q-Pad could revolutionize how women manage and monitor their health.
In 2024, IUD insertion became a focal point of debate, driven by women sharing painful experiences on TikTok. While many healthcare providers have described the procedure as minimally painful, viral videos of women leaving appointments in tears or bleeding challenged this narrative and prompted the CDC to act. The CDC’s new guidelines emphasize open communication between patients and providers, addressing pain concerns and discussing management options. A key update includes recommending topical lidocaine, a less invasive anesthetic, applied to the cervix to reduce discomfort during the procedure. In response to this move, companies are developing technologies that can make IUD insertion more comfortable. ASPIVIX, a leading innovator in gynecological and fertility solutions, created a new device which could reduce the pain associated with IUD insertion. The device, called Carevix™, uses suction to grasp the cervix during the IUD insertion procedure as an alternative to the traditional tenaculum, which looks like a pair of scissors tipped with hooks. “I am really excited and grateful for ASPIVIX’s Carevix,” Anushay Hossain, a writer, feminist policy analyst specializing in women’s health legislation and the host of the podcast The Pain Gap, says. “We know that women experience painful, excruciating IUD insertion procedures, and their suffering is ignored and dismissed.” Hossain argues that a procedure as common as IUD insertion should not be so needlessly painful. She adds that the fact it’s only now being addressed highlights a troubling cultural tolerance for women’s suffering—one that remains far too high. However, she predicts Carevix is just the beginning, and we will continue to see more attention focused on how doctors handle routine procedures. “Society drives culture and vice versa. America is a lot more conservative than we like to think, and it really hinders all things women's health,” Hossain says. “It impacts how we view women's sexuality and bodily autonomy. I hope after this last election, we wake the hell up to the truth about America's real culture.” In September, ASPIVIX announced a partnership with Tia, a network of women’s health clinics in the U.S., to enhance IUD procedures and improve patient experiences. The collaboration will introduce Carevix to nine Tia clinics across Los Angeles, New York, San Francisco and Scottsdale. This marks the first time Carevix™ will be available in the U.S., offering women a more comprehensive and comfortable care experience. “With the CDC urging physicians to better manage pain during IUD procedures, our partnership with Tia represents a victory for women advocating for better care. It’s an important step for ASPIVIX as we continue to align our patient-centric solution,” Ikram Guerd, U.S. general manager of ASPIVIX, wrote in a press release.
Chief Medical Officer at Midi Health
DR. Kathleen Jordan
Women are now taking charge of their health by monitoring their own blood pressure with wearables, tracking glucose levels and testing hormone levels through at-home collection tests.
Writer
Anushay Hossain
Society drives culture and vice versa. America is a lot more conservative than we like to think, and it really hinders all things women's health. It impacts how we view women's sexuality and bodily autonomy. I hope after this last election, we wake the hell up to the truth about America's real culture.
In 2025, healthcare access and equity will remain key issues, but innovative solutions are emerging to break down barriers, particularly for women. Digital health platforms, telemedicine and AI tools are expanding access, allowing women—especially those in underserved areas—to connect with vital healthcare resources. Companies like Maven, Elektra Health and Carrot Fertility are already ahead of the curb with their community-driven care models that ensure care is culturally relevant and responsive to women's needs. Equity will shift from a goal to a measurable outcome, with systems held accountable for delivering inclusive, culturally competent care. The focus will be on ensuring all women, regardless of socioeconomic status, race or location, have access to the resources they need for optimal health, creating a more equitable and supportive healthcare environment.
Data from the Association of American Medical Colleges (AAMC) projects that the United States will face a physician shortage of up to 124,000 by 2034, as demand for physicians continues to outpace supply. Compounding this issue, maternity care deserts are expanding, leaving more pregnant women struggling to access essential care in their states. What’s more, the U.S. has the highest maternal death rate among high-income countries. According to data from JAMA Network, between 2006 and 2020, over 400 maternity services across the country closed their doors. In a troubling development, 11 health systems announced the closure of their obstetric services between March and June 2022, citing low birth volumes and staffing shortages. In 2025, telehealth platforms are expected to expand into rural and underserved areas, leveraging broadband initiatives and mobile technology to close the care gap. Women in remote areas will have greater access to specialists in areas like maternal health, menopause and mental health, ensuring timely interventions. Startups will play a pivotal role in advancing women’s healthcare by driving innovation and addressing gaps in care. These companies are leveraging cutting-edge technology to create solutions that cater specifically to women’s unique health needs. From personalized health apps and telehealth platforms to AI-driven diagnostics and wearable devices, startups are offering women more control over their health, from preventive care to chronic disease management. “I'm very excited by the role we're seeing the private sector, particularly startups, play in women's health,” Miller Morris, the founder and CEO of the Comma Collective, an integrated period care company, says. “From unicorns like the Maven Clinic to early-stage ventures like us at Comma, we're seeing startups build solutions that center women first.” To drive meaningful progress in women’s healthcare, Morris emphasizes that companies must prioritize the needs of people and communities. Startups, with their agility and innovation, are uniquely positioned to do this, offering flexibility that larger corporations, research institutions and healthcare enterprises often lack. “In the U.S., we're seeing some paradoxes unfold in real time: on one hand, we have more resources put toward women's health than ever,” Morris says. “More female scientists, founders and funders than ever. On the other hand, there is a real threat to reproductive rights, as well as a cultural resurgence of traditional gender norms.” For true gender equality, particularly in healthcare, Morris explains that startups must merge innovation with lived experience. It's crucial to ask: What do women truly want, and what innovations have we yet to imagine? By aligning new ideas with real-world needs, startups can pave the way for more equitable healthcare solutions.
Insurance Innovations
Comprehensive Approach to Pharmacies
Telehealth Beyond Urban Centers
In 2025, experts predict policymakers and private insurers will collaborate to roll out more inclusive health plans, expanding coverage for conditions like endometriosis, fibroids and infertility. Sliding-scale pricing models and increased subsidies for low-income individuals will also reduce financial barriers to care. One company that is already implementing this is Flora Fertility, the first direct-to-consumer insurance solution for fertility and women's health. The fertility industry, valued at $23.5 billion and on an upward trajectory, addresses one of the most pressing health issues worldwide, with one in five individuals globally affected by fertility challenges. As this sector grows, it reflects a significant demand for solutions that support individuals and couples navigating difficulties in conception. “There’s a massive opportunity for innovation and support to help couples and individuals grow their families; however, a major hurdle remains cost,” Laura McDonald, co-founder of Flora Fertility, says. “Fertility treatments often exceed $30,000 per pregnancy, if one is even achieved. There are no guarantees, creating huge financial stress. What’s more, a majority of people pay with credit cards or high-interest loans, increasing the cost further.” Although some large employers provide fertility coverage, McDonald notes that over 60% of individuals lack this benefit, particularly gig workers and contract employees. As the modern workforce continues to evolve, so do the needs of today's consumers. Lane emphasizes that this shift requires a corresponding change in how we finance and access care. “Flora is filling the funding and accessibility gap by bringing individually-owned fertility insurance coverage straight to the hands of consumers, providing women and families with financial freedom and reproductive autonomy,” McDonald says. “By proactively planning for their future fertility risk, they can focus on other things—ike travel, home and career—before they decide to start a family.” Fertility treatments are extremely expensive for the typical consumer, which is why 80% indicate this being a highly valued employee benefit. And yet, most companies cannot afford to offer comprehensive fertility group plans unless they have 1,000 employees or more. “Infertility rates are continuing to climb across the globe, meaning new methods for funding treatment are paramount,” Dr. Christy Lane, co-founder of Flora Fertility, says. “For millennials and Gen-Z who are increasingly delaying their childbearing years, the focus will be on preparing without fear.” Looking ahead, both McDonald and Lane see more companies like their own emerging to provide quality healthcare without breaking the bank. “Insurance policies, like that of Flora, offer a modern and uplifting, community-driven approach to insurance for one of the biggest growing health categories and demands of Gen-Z: their ability to build a family when they choose,” McDonald says. “We essentially allow women to come together to fund one another’s fertility risk—and what’s more powerful and uplifting than that?”
As we enter 2025, one of the most promising shifts in women’s healthcare will be the transformation of pharmacies into comprehensive health hubs. Far beyond the traditional role of dispensing medications, pharmacies will increasingly serve as accessible, community-based centers for personalized care, providing women with the tools and resources needed to manage their health across all stages of life. “The women’s health pharmacy aisle has been in need of an update. As we enter this new age of self-agency, we will be seeing more brands incorporating a digital-first and comprehensive approach to women’s health that not only addresses the unique needs of individuals, but also leaves no room for confusion,” Jamie Norwood, co-founder of Winx Health, says. Winx, which is a pioneering hub for sexual wellness and reproductive health, delivers a range of products—including pregnancy tests, UTI and yeast infection treatments and the morning-after pill—directly to your door. Norwood says that bringing more at-home tests to the retail space, as well as furthering access to education, will promote a more personalized approach to healthcare, as women will feel empowered through knowledge and be able to advocate for themselves with confidence. Without access, these innovations don't mean much, as they won’t be reaching the people who need it most. “Nearly 50% of counties across the U.S. do not have access to an OB-GYN, leaving women in care deserts, further amplified by a growing sexual health education gap. The rise in at-home testing options, like the UTI Test + Treat from Winx Health, helps to close the care equity gap to provide solutions within reach,” Norwood explains. Norwood says these at-home testing options allow women to understand what’s going on in their bodies in the comfort of their own homes, as well as offer access to same day prescription treatment, all without having to take time out of their workdays. Another company that does this well is Wisp, which offers same-day pharmacy pick-up for birth control, yeast infection treatment, UTIs and much more. Norwood believes companies like hers and Wisp will continue to grow and potentially revolutionize the way women diagnose infections and get treated, helping women take control of their well-being in ways that are convenient, cost-effective and tailored to their unique needs.
Founder & CEO OF Comma Collective
Miller Morris
I'm very excited by the role we're seeing the private sector, particularly startups, play in women's health. From unicorns like the Maven Clinic to early-stage ventures like us at Comma, we're seeing startups build solutions that center women first.
Co-Founder OF Winx Health
Jamie Norwood
Nearly 50% of counties across the U.S. do not have access to an OB-GYN, leaving women in care deserts, further amplified by a growing sexual health education gap. The rise in at-home testing options, like the UTI Test + Treat from Winx Health, helps to close the care equity gap to provide solutions within reach.
According to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM), only 8% of NIH research funding is allocated to women’s health—down from 11% in 2019
According to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM), only 8% of NIH research funding is allocated to women’s health—down from 11% in 2019. As we look ahead to 2025, the landscape of women’s health is poised for a transformative shift, largely fueled by groundbreaking research and targeted funding initiatives. “I believe that 2025 will be one of an awakening of the needs in women’s health,” Gloria Kolb, CEO and co-founder of Elitone, an FDA-cleared treatment that aids in restoring pelvic floor health, says. “This is stemmed by the increasing press in grants, spurred by the federal administration, and, now so, by private groups such as Pivotal Ventures’ $250M call.”
Many experts argue that the future of research funding in women’s health depends on femtech companies, particularly as a new administration, with a history of policies that have been less supportive of women’s health, takes office. These innovative companies are positioned to lead the charge in advancing critical research, filling the void left by traditional funding sources. To address these systemic challenges, Sheena Franklin, founder of K’ept, says femtech companies are moving beyond their technology solutions by advocating for policy changes, developing awareness campaigns and fostering collaboration. “They’re partnering with educational institutions, nonprofits and community organizations to provide resources and programs,” Franklin says. “In the future, we will see more partnerships with government agencies, pharmaceutical companies and insurers, as femtech companies are ushering in a new way of ‘doing business’ across the healthcare ecosystem.” Anna Butterworth, a femtech pioneer and founder of and founder of the first global agency dedicated to trend forecasting in women's health and femtech, Ultra Violet, shares Franlin's viewpoint, noting that the venture capital industry has yet to keep pace with the rapid growth and innovation happening in women’s health. “In 2023, women's health companies received just 2% of the $41.2 billion in venture capital (VC) funding that went to health companies,” Butterworth says. “This is staggeringly out of step with the opportunity of the industry. It’s stunting the innovation and speed of sector growth, but thankfully we’re seeing FemTech brands buck the trend and demonstrate the value of the market.” Despite rising interest, femtech continues to receive limited venture capital funding. However, according to Statista, femtech investment is expected to reach $103 billion by 2030. “Advocacy efforts aim to shift investor perspectives, emphasizing the significant market potential of women’s health innovations, while public-private partnerships are emerging to bolster funding in underserved areas,” Dr. Kate Burke, senior medical advisor at PatientsLikeMe, says.
Hormonal Health and Menopause
CARDIOVASCULAR hEALTH
bRAIN hEALTH
FemTech and Digital Health Innovation
As awareness around menopause and perimenopause grows, research will focus on developing better treatments for managing symptoms, such as hot flashes, mood swings and cognitive decline. More funding will be directed toward exploring hormonal therapies and alternative interventions that are safer and more effective for women at different life stages. In May, a new study was published concluding that the benefits of hormone therapy for treating menopause symptoms outweigh the risks. More than two decades ago, menopause hormone therapy (MHT) was the go-to treatment for women experiencing menopause in the United States. However, that all changed when the Women's Health Initiative (WHI) study released shocking results that raised concerns about its safety and effectiveness. Researchers now know that when used appropriately, hormone therapy can provide significant benefits in managing menopause symptoms, with risks that are better understood and more manageable. Similarly, vaginal estrogen faced backlash due to an outdated "boxed" warning that suggested severe health risks, such as strokes, blood clots and potential dementia. Multiple studies have since debunked that claim, yet the warning still remains on the label. “Women will spend 40% of their lives in menopause but less than 20% of physicians in the U.S. are trained to treat it?” Anushay Hossain, a writer, feminist policy analyst specializing in women’s health legislation and the host of the podcast The Pain Gap, says. “The lack of research and training alone in healthcare for women is criminal. We don't know what we don't know.” Although there are so many gaps within women’s health, Hossain says she’s optimistic and heartened by all the progress that was made in 2024. “With the White House committing so much funding and research to women's health, we are on a roll,” Hossain says. “I'm so excited about perimenopause and menopause getting the attention it deserves because it really encapsulates everything that is wrong regarding the criminal lack of research and how long women have been suffering needlessly.”
Cardiovascular Health
Research into cardiovascular health is increasingly focusing on the gender-specific ways heart disease manifests in women. Unlike men, women experience heart disease, which is the leading cause of death for women, differently. Studies are now examining how hormones like estrogen play a protective role in women’s cardiovascular health, particularly before menopause. A study published in August in the New England Journal of Medicine found that measuring three biomarkers—CRP, LDL cholesterol and Lp(a)—in a woman’s bloodstream could help predict her risk of heart attack, stroke and other cardiovascular events. This study could help identify heart disease in women by providing a more accurate and personalized approach to assessing cardiovascular risk. By testing for those three key biomarkers, doctors could gain valuable insights into a woman’s likelihood of experiencing heart disease. A study published in the National Library of Medicine emphasized the crucial role estrogen plays in heart health. Estrogen is known to provide protective benefits to women's hearts, but this protection decreases after menopause, raising the risk of cardiovascular diseases. The study also revealed that the expression of certain proteins varies between genders, which helps explain the lower incidence of heart disease in premenopausal women compared to men. With researchers continuing to focus on heart health, particularly in women, advancements in early detection, personalized treatments and understanding gender-specific risk factors are paving the way for more effective prevention and care.
In 2024, several significant initiatives aimed at advancing women's health research and funding were announced. The White House launched its first-ever initiative on women’s health research to address the historical underrepresentation of women in medical studies. The Department of Defense committed $500 million to support research focused on women’s health, particularly for those in the military, and the Biden-Harris Administration’s Advanced Research Projects Agency for Health (ARPA-H) allocated $110 million to accelerate innovations in women's health. In addition, Congresswoman Nikema Williams, a Democrat from Georgia’s 5th District, reintroduced the bipartisan Endometriosis CARE Act. Originally introduced in 2022 by Illinois Rep. Lauren Underwood, the bill calls for a significant increase in funding for endometriosis research. The updated bill aims to allocate $50 million each year to advance research and improve access to treatment for those affected by endometriosis. While Kolb remains hopeful, she’s also realistic, emphasizing that securing funding is crucial to advancing ongoing research. “Research is a slow process, so likely there won’t be much change on the research side that is visible,” Kolb tells Flow Space.“Hopefully, with the bright outlook on increased mergers and acquisitions in 2025, the femtech and women’s health space will see more successful exits. The exits are needed to fuel funding by the investors.” From the advancement of precision medicine to a stronger focus on diseases and conditions that disproportionately impact women, including menopause, it’s clear that research funding is essential to driving a new era of discovery. This focus on women’s health will not only address long-standing gaps in knowledge but also empower new generations of scientists and clinicians to challenge the status quo and pave the way for a more equitable healthcare system.
In 2025, research into women’s brain health is expected to make significant strides, focusing on both gender-specific conditions and innovative treatment approaches. One key area of exploration is the link between hormonal changes and cognitive decline. Research is increasingly examining how fluctuations in estrogen during perimenopause and menopause may impact memory, mood and cognitive function, with some studies suggesting that estrogen’s protective effects on the brain diminish after menopause, potentially increasing the risk of Alzheimer's and other neurodegenerative diseases. In June, a study was published in JAMA Neurology, revealing a significant connection between a maternal history of dementia and elevated levels of amyloid-beta in the brain, a key marker linked to Alzheimer’s disease. This new information underscores the potential genetic influence of mothers in the transmission of the debilitating condition. Researchers are also exploring the potential benefits of lifestyle factors—such as diet, exercise and sleep—on brain health, particularly in aging women, with studies showing that maintaining physical and mental activity can help mitigate cognitive decline. Studies like these are crucial for advancing women’s health by shedding light on the unique ways hormonal changes and genetics impact brain health. By uncovering the link between estrogen and cognitive decline, we’re one step closer to personalized treatments for women, especially as they age. This could lead to more targeted interventions during perimenopause and menopause, a time when women are particularly vulnerable to brain-related conditions like Alzheimer’s.
Brain Health
Women will spend 40% of their lives in menopause but less than 20% of physicians in the U.S. are trained to treat it?
FemTech pioneer & founder of Ultra Violet
Anna Butterworth
In 2023, women's health companies received just 2% of the $41.2 billion in venture capital (VC) funding that went to health companies. This is staggeringly out of step with the opportunity of the industry. It’s stunting the innovation and speed of sector growth, but thankfully we’re seeing femtech brands buck the trend and demonstrate the value of the market.
The landscape of women’s health medications is set to undergo a major transformation in 2025, driven by new discoveries and an increased focus on gender-specific needs. One of the most notable shifts in 2024 was the uptick in the use of GLP-1 medications, which, traditionally used to manage diabetes, have shown promising benefits for weight management and metabolic health. Additionally, 2024 saw the introduction of new treatments for sexual dysfunction associated with menopause, such as innovative hormone therapies and non-hormonal options like Vyleesi, aimed at enhancing libido and sexual satisfaction for women experiencing menopausal changes. With advancements in drug development and personalized medicine, researchers are working to create treatments that better address the unique health challenges women face. From targeted therapies for menopause to groundbreaking treatments for conditions like osteoporosis and cardiovascular disease, the future of women’s health drugs promises more effective, safer options that go beyond one-size-fits-all solutions.
For women, particularly those navigating the challenges of menopause or dealing with obesity, GLP-1s are proving to be a game changer. These medications help reduce appetite, improve insulin sensitivity and aid in weight loss, which can, in turn, lower the risk of conditions like heart disease, diabetes and certain cancers that disproportionately affect women. However, experts believe GLP-1s have the potential to do much more than aid in weight loss. They may also offer benefits for managing inflammatory and autoimmune conditions, mood disorders, neurodegenerative diseases and beyond. “GLP-1s show potential in treating various autoimmune conditions through their powerful anti-inflammatory effects and immune system modulation,” Amy Reichelt, Ph. D., a nutritional neuroscientist, tells Flow Space. “In conditions like lupus and rheumatoid arthritis, autoimmune medications appear to reduce pro-inflammatory cytokines and enhance regulatory T-cell function, helping restore immune system balance.” Early research suggests GLP-1s could in fact reduce joint inflammation in rheumatoid arthritis, while helping manage systemic symptoms across these conditions, according to a 2024 study from the British Society for Rheumatology. In regards to neurodegenerative diseases, research shows that GLP-1s could potentially slow the progression of Alzheimer's and Parkinson's, according to research published in the National Library of Medicine. “GLP-1s appear to enhance brain plasticity and promote neuronal survival, while also improving insulin signaling in the brain,” Reichelt tells Flow Space. “This could lead to better cognitive function and memory, potentially slowing the progression of neurodegenerative diseases like Alzheimer's and Parkinson's.” Apart from this, there has also been growing research into how GLP-1s can address polycystic ovary syndrome (PCOS) which affects 8% to 13% of women of reproductive age. Up to 70% of PCOS cases are undiagnosed, and it’s estimated that five to six million women have PCOS in the U.S. “I believe that GLP-1s have the potential to significantly improve women’s health over the next decade with the right dedicated research,” Dr. Rekha Kumar, a triple board-certified endocrinologist and medical director of the American Board of Obesity Medicine, says. “GLP-1 medications have been particularly successful in treating women with PCOS, which has historically been a challenging condition to address.” Kumar says as access and interest in these drugs has increased, so has the research on how they really work, leading to discoveries around other health conditions they can help treat. While obesity and weight management present clinical challenges for both men and women, they are profoundly shaped by female biology. Hormonal fluctuations during perimenopause and menopause significantly affect metabolism, insulin sensitivity and fat distribution, contributing to higher rates of obesity in women compared to men. Dr. Kathleen Jordan, chief medical officer at Midi Health, says these biological factors make weight management uniquely complex for women, particularly during midlife. “Women between the ages of 40 to 59 have the highest incidence of obesity—and it’s no coincidence that this coincides with menopause,” Jordan says. “This new class of medications are achieving results in obesity treatment that we have never come close to approaching prior to these medications hitting the market.”
READ MORE
In 2025, innovation will be the driving force transforming women’s health from reactive care to a proactive, personalized experience.
Non-Hormonal Treatments for Menopause Symptoms
Sexual Health
Neuroprotective Drugs
GLP-1s
As more women seek alternatives to traditional hormone therapy, non-hormonal treatments like Veozah (fezolinetant), a selective neurokinin receptor antagonist, are gaining traction for managing hot flashes and other vasomotor symptoms (VMS) of menopause. In May, Bayer unveiled Elinzanetant, a promising new drug that has demonstrated impressive results in early trials, significantly reducing the frequency and severity of moderate to severe hot flashes linked to menopause. These drugs target the brain’s thermoregulatory center without impacting hormone levels, offering a safer option for women who cannot or prefer not to use hormones. The introduction of these treatments reflects a broader trend in menopause care: a focus on individualized options that cater to a diverse range of needs. Early trials of Elinzanetant and similar drugs like Veozah have shown promising results, with women reporting significant reductions in the frequency and intensity of hot flashes, as well as improved sleep and overall quality of life. As research continues, we can expect more innovative non-hormonal solutions to enter the market, expanding the toolbox for managing menopause and empowering women with choices that align with their personal health priorities. These advancements mark a pivotal moment in addressing a long-neglected area of women’s health, signaling a shift toward treatments that are not only effective but also accessible and inclusive.
The conversation around sexual health for menopausal women has long been overlooked, but recent advancements signal a positive shift. Last year marked a significant milestone with the introduction of new therapies addressing sexual dysfunction, including Vyleesi (bremelanotide). This medication, designed to enhance sexual desire in premenopausal women, has opened the door to a broader understanding of the complexities of female sexual health. Sexual dysfunction during menopause often stems from a combination of factors, including declining hormone levels, vaginal dryness, pain during intercourse and shifts in mood and energy. Hormonal changes, particularly the drop in estrogen and testosterone, also play a key role in diminishing libido and arousal. Looking ahead to 2025, emerging therapies are likely to include a mix of hormonal options, such as localized estrogen and testosterone products, alongside non-hormonal solutions targeting the brain’s neurotransmitter pathways. For example, drugs similar to Vyleesi that modulate brain chemistry to enhance desire and arousal may expand in their applications. Additionally, we expect advancements in vaginal health products, including next-generation lubricants, moisturizers and laser-based therapies, to address pain and dryness more effectively. This growing focus on sexual health for menopausal women represents a long-overdue acknowledgment of its importance to overall well-being.
The link between hormonal changes and brain health is driving advancements in neuroprotective treatments for women, particularly during menopause when estrogen levels decline. This hormonal shift has been associated with an increased risk of cognitive decline and Alzheimer’s disease, conditions that disproportionately affect women. In 2025, we anticipate breakthroughs in drugs that mimic estrogen’s brain-protective effects without the risks tied to traditional hormone therapy. Selective estrogen receptor modulators (SERMs) are at the forefront, designed to safeguard memory and cognitive function while minimizing side effects. Recent developments, such as the FDA approval of Leqembi (lecanemab) for early-stage Alzheimer’s, mark a significant step forward. Leqembi targets amyloid-beta plaques in the brain, a key marker of Alzheimer’s, and offers hope for women with a family history of dementia, particularly when maternal links may elevate risk. These emerging therapies, combined with lifestyle interventions like improved sleep, diet and exercise, could redefine brain health strategies for women, empowering them to mitigate cognitive decline and enhance quality of life.
nUTRITIONAL Neuroscientist
Amy Reichelt, PH.D
GLP-1s show potential in treating various autoimmune conditions through their powerful anti-inflammatory effects and immune system modulation.
In recent years, the intersection of policy and women’s health has been marked by both progress and challenges. As 2025 approaches, the role of legislation in shaping the future of women’s healthcare has never been more critical. Policies addressing workplace accommodations, insurance coverage for essential treatments and funding for research are at the forefront of advocacy efforts.
As the conversation around menopause becomes more mainstream, expect an increase in policies supporting midlife women in the workplace. This may include mandatory menopause training for employers, workplace accommodations for menopausal symptoms and anti-discrimination protections. One company that has already begun implementing those policies is OLLY. “My experience with menopause opened my eyes to the larger need for both physical and emotional support for this condition,” Hanneke Willenborg, CEO at OLLY, tells Flow Space. “I realized that not only is there a gap in the product market for menopause support—an experience all women go through—but there is also a gap in our workplace support.” A Mayo Clinic study released in 2023 estimates that menopause costs American women $1.8 billion annually in lost working time. The study, the largest of its kind in the U.S., explored how menopause symptoms like hot flashes, night sweats and mood swings impact women in the workplace. The study surveyed over 4,000 participants across Mayo Clinic sites in Minnesota, Arizona, Florida and Wisconsin. Approximately 15% reported missing work or cutting back hours due to menopause symptoms, which researchers classified as "adverse work outcomes." Women experiencing the most severe symptoms were 16 times more likely to face these challenges compared to those with milder symptoms. Alarmingly, more than 1% of participants revealed their symptoms were so debilitating that they had either quit their jobs or been laid off within the past six months. Willenborg emphasizes that her goal is not just to support employees but also to foster open conversations about menopause within the workplace and the broader community. By offering flexible work hours, remote work options and in-office accommodations tailored to women experiencing menopause, she aims to create a more inclusive and understanding work environment. “Women’s health topics are often still stigmatized to talk about. I even feel as CEO, I shouldn't be talking about menopause,” Willenborg said. “There's always this little voice in my head that says, ‘do your job, run your business, and don't talk about these things’. But I realized that if I want to create a truly open and safe space where people can be the real version of themselves, I need to be the real version of myself.” Willenborg aims to be an inspiration for other companies and hopes more will recognize menopause as a significant and impactful stage in a woman's life. “I don’t think women realize that menopause isn’t something you just have to endure and not talk about,” she says. “We need to do a better job of educating and supporting women during this time.”
Abortion Access
Insurance Coverage Expansion
Menopause Workplace Rights
In 2025, reproductive rights and healthcare access will continue to be a highly contentious issue in the U.S., with significant legislative and administrative shifts likely to unfold. Following the Supreme Court's 2022 decision to overturn Roe v. Wade, the responsibility for regulating abortion access was returned to individual states, resulting in a fragmented landscape of laws. Some states have passed restrictive abortion laws, while others have implemented measures to protect abortion rights. As the year progresses, state-level policies are expected to become more entrenched. Some states may enact stronger protections for abortion access, while others may introduce even more restrictive laws, driven by political pressure. However, with a new Trump administration in power, it’s anticipated that the federal government will push for policies that further erode abortion protections, making it more difficult for women to access essential reproductive healthcare. “With restrictions tightening, especially post-Dobbs, many women will continue to face more and more barriers to accessing safe abortion care,” Kavelle Christie, the director of the Gender Equity & Health Justice Program at Community Catalyst, says. “Some progressive companies might step up to provide coverage for travel-related expenses, but honestly, these benefits will remain a rare exception.” Christie believes abortion access is still likely to be out of reach for many, especially in more conservative states, unless there’s a significant shift in federal or state-level policy. “Without sweeping legislation, the U.S. will likely stay at a critical juncture where access to abortion care remains highly unequal,” Christie says. While federal intervention can influence broad policy, states still retain significant power within their borders to protect rights through legislation, legal challenges, executive actions and funding decisions. States like California and New York have passed laws that protect abortion access, while states like Texas and Georgia have implemented some of the strictest abortion bans in the country. Moving forward, it will be interesting to see how states will continue to protect their own abortion laws and what strategies they may employ to counteract any federal efforts to restrict access. As political pressures grow, states will likely become battlegrounds for both legal and legislative challenges, with the outcome shaping the future of reproductive rights in the U.S.
With the rise of non-hormonal therapies, innovative GLP-1 drugs and treatments for conditions like endometriosis and fibroids, advocates are pushing for broader insurance coverage to ensure these therapies are accessible to all women. As more treatment options emerge, especially those targeting menopause symptoms, policymakers are facing increased pressure to mandate insurance coverage for these essential medications and technologies. For instance, non-hormonal treatments for menopause, such as fezolinetant, and medications for conditions like fibroids are often not fully covered by many insurance plans, leaving women with significant out-of-pocket expenses. This lack of coverage creates a barrier to accessing critical healthcare that can greatly impact women’s quality of life. Louisiana is one state taking action in this area, recently passing a law that requires Medicaid and private health insurance plans to cover menopause and perimenopause treatment. This legislation is expected to improve access to hormone replacement therapy (HRT) for those in need. As more states and policymakers recognize the importance of comprehensive coverage for menopause-related treatments, it’s likely that the conversation will shift toward addressing these gaps in access and ensuring that women can receive the care they need without financial hardship. Expanding insurance coverage to include these therapies could be transformative in improving women’s health outcomes and reducing long-standing disparities in care. “The next few years will likely bring continued struggles for access to reproductive healthcare, affordable fertility treatments, paid family leave and maternal care,” Christie says. “Ultimately, the key to progress will lie in continued advocacy, pressure on both the public and private sectors and persistent calls for better funding and more inclusive healthcare policies.”
CEO of OLLY
Hanneke Willenborg
I don’t think women realize that menopause isn’t something you just have to endure and not talk about. We need to do a better job of educating and supporting women during this time.
director of the Gender Equity & Health Justice Program at Community Catalyst
kavelle Christie
The next few years will likely bring continued struggles for access to reproductive healthcare, affordable fertility treatments, paid family leave and maternal care. Ultimately, the key to progress will lie in continued advocacy, pressure on both the public and private sectors and persistent calls for better funding and more inclusive healthcare policies.
